Semaglutide News and Research

Latest Semaglutide News and Research

Exploring the therapeutic potential of flavonoids in type 2 diabetes

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin resistance, β-cell dysfunction, and impaired glucose homeostasis.

20 Mar 2025

Early use of anti-obesity medication doubles weight loss

Adding an anti-obesity medication just one month after behavioral therapy begins-rather than waiting the currently recommended six months-can more than double weight loss for patients who struggle initially with lifestyle changes alone, according to new research published in Nature Medicine from a team at the Perelman School of Medicine at the University of Pennsylvania.

18 Mar 2025

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

To tackle the inequity in medication access, a societal issue especially in developing nations, a team of undergraduate student-researchers at the University of Ottawa has developed a new biomanufacturing platform called Phytogene.

18 Mar 2025

Keto controversy? Experts say it’s here to stay

Low-carb and ketogenic diets offer sustainable solutions for chronic disease, enhancing metabolic health and supporting weight loss through dietary changes.

18 Mar 2025

Novel cyclic peptide antagonist can be a promising therapeutic approach for MASH

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.

14 Mar 2025

New insights into screening and treatment for diabetic retinal disease

Diabetes affects more than 1 in 10 adults worldwide and has been accompanied by an increase in vision-threatening diabetic retinal disease.

12 Mar 2025

Tirzepatide helps people without diabetes lose 13% body weight in real-world study

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at least six months lost an average of 12.9% of their body weight. The study highlights Tirzepatide’s potential as an effective off-label obesity treatment before its formal FDA approval for weight loss.

11 Mar 2025

Integrated anti-aging strategy could reduce neurodegeneration

Aging significantly impacts neurodegeneration, increasing risks for diseases like Alzheimer's. Research focuses on therapies to enhance cognitive function.

11 Mar 2025

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 diabetes patients, especially compared to insulin. The study also highlights GLP-1RAs’ potential as a cancer-protective treatment, independent of glucose control.

9 Mar 2025

Naturally occurring molecule suppresses appetite and promotes weight loss

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide - also known as Ozempic - in suppressing appetite and reducing body weight.

6 Mar 2025

Study shows benefits of GLP-1 drugs for kidney transplant recipients with type 2 diabetes

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

5 Mar 2025

Surgery first strategy could lead to better weight loss outcomes

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery, suggesting that a surgery first strategy could lead to better outcomes.

5 Mar 2025

Researchers discover neural mechanism behind leptin resistance and a way to reverse it

Worldwide obesity rates have more than doubled since 1990, with nearly a billion people now falling into the category.

4 Mar 2025

Breakthrough research uncovers way to maintain metabolism during calorie restriction

Many people who have tried to lose weight by cutting calories are familiar with this frustrating reality: at some point, the body stops shedding pounds.

3 Mar 2025

New study confirms GLP-1 medications are safe for mental health in diabetes

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 diabetes patients.

2 Mar 2025

New study identifies brain circuit key to reducing cocaine-seeking behavior

Imagine a future where the grip of cocaine use disorder can be loosened, where cravings fade, and the risk of relapse diminishes.

27 Feb 2025

With RFK Jr. in charge, supplement makers see chance to cash in

Last fall, before being named the senior U.S. health official, Robert F. Kennedy Jr. said the Trump administration would liberate Americans from the FDA's "aggressive suppression" of vitamins, dietary supplements, and other substances — ending the federal agency's "war on public health," as he put it.

25 Feb 2025

Genetic study demonstrates fat-selective weight loss with GLP-1 agonist use

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar levels and aiding weight loss due to their unique pharmacological mechanisms.

25 Feb 2025

Understanding the impact of weight loss medications on female reproductive health

In recent months, the efficacy of contraception for people taking weight loss medications has been questioned, as several women claim to have gotten pregnant despite using oral contraceptives.

21 Feb 2025

Regulatory crackdown on online prescriptions of weight-loss drugs

Online pharmacies must now conduct in-person consultations before dispensing weight-loss medications, ensuring safe and appropriate use of high-risk drugs.

19 Feb 2025

Semaglutide News and Research

Latest Semaglutide News and Research

Exploring the therapeutic potential of flavonoids in type 2 diabetes

Early use of anti-obesity medication doubles weight loss

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

Keto controversy? Experts say it’s here to stay

Novel cyclic peptide antagonist can be a promising therapeutic approach for MASH

New insights into screening and treatment for diabetic retinal disease

Tirzepatide helps people without diabetes lose 13% body weight in real-world study

Integrated anti-aging strategy could reduce neurodegeneration

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Naturally occurring molecule suppresses appetite and promotes weight loss

Study shows benefits of GLP-1 drugs for kidney transplant recipients with type 2 diabetes

Surgery first strategy could lead to better weight loss outcomes

Researchers discover neural mechanism behind leptin resistance and a way to reverse it

Breakthrough research uncovers way to maintain metabolism during calorie restriction

New study confirms GLP-1 medications are safe for mental health in diabetes

New study identifies brain circuit key to reducing cocaine-seeking behavior

With RFK Jr. in charge, supplement makers see chance to cash in

Genetic study demonstrates fat-selective weight loss with GLP-1 agonist use

Understanding the impact of weight loss medications on female reproductive health

Regulatory crackdown on online prescriptions of weight-loss drugs

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Semaglutide News and Research

Latest Semaglutide News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in